
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher is a well-established and diversified manufacturing company with a strong focus on the life sciences and diagnostic industries. Recent divestitures have resulted in a streamlined and more focused portfolio, with the company's newest acquisition, Cytiva, demonstrating strong core revenue growth in the biotechnology segment. The company's strong earnings and solid management track record, along with significant opportunities for growth in the life sciences and diagnostic markets, make it an attractive investment opportunity.
Bears say
Danaher is a company that has undergone significant transformation over the past few decades through mergers, acquisitions, and divestitures, now primarily focusing on manufacturing scientific instruments and consumables for the life sciences and diagnostic industries. In recent years, the company has faced challenges, including a decline in respiratory testing revenue and the divestiture of its environmental and applied solutions segment. Despite positive commentary on reshoring and a recovery in biotech funding, there are concerns about the company's ability to rebound in key segments, leading to a negative outlook on the stock. Additionally, there may be potential risks related to the integration of recent acquisitions and a slowdown in overall demand for life science instruments.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares